EUCTR2004-002505-74-FI进行中（未招募）1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.
Cephalon Europe, A Division of Cephalon UK Limited0 个研究点目标入组 150 人开始时间: 2004年12月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(a) written informed consent/assent is obtained
- •(b) a boy or girl aged 6 to 16 years, inclusive
- •(c) meet the minimal criteria established by the International Classification of Sleep Disorders (ICSD) manual of the American Academy of Sleep Medicine (AASM) for narcolepsy (or presumed narcolepsy) or OSAHSORhave a previous diagnosis of narcolepsy or OSAHS within 2 years of the screening visit
- •(d) have a complaint of ES
- •(e) are in good health as determined by a medical and psychiatric history, physical examination, ECG, and clinical laboratory tests
- •(f) have blood pressure values greater than those for the 5th percentile and less than the 95th percentile on the National High Blood Pressure Education Program guidelines for blood pressure levels for boys and girls ages 6 to 16 years
- •(g) girls who are postmenarche or sexually active, have a negative urine pregnancy test at screening, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 2 cycles after participation in the study); acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptives (oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
- •(h) able to swallow a tablet similar in size and shape to the study drug tablet
- •(i) negative urine drug screen (UDS) for any illicit drug, alcohol (ethanol), stimulants at screening; if positive for stimulants (prescribed for excessive sleepiness) at screening, UDS to be repeated after a washout period and before baseline
- •(j) have a parent or legal representative who is willing to participate in the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(a) have self-induced sleep deprivation/poor sleep hygiene
- •(b) have a past or present seizure disorder (except history of a single febrile seizure), a history of psychosis, or of clinically significant head trauma (eg, brain damage) or past neurosurgery
- •(c) have a history of suicide attempt, or are at suicidal risk
- •(d) a clinically significant drug sensitivity to stimulants such as amfetamine, dexamfetamine, or methylphenidate; and/or modafinil or any of its components
- •(e) use of any monoamine oxidase (MAO) inhibitors or selective serotonin reuptake inhibitors (SSRIs) within 2 weeks of the baseline visit (NOTE: SSRIs will be allowed if the patient has been on a stable dose for at least 1 month.)
- •(f) received any investigational drug (except modafinil) within 4 weeks of the baseline visit
- •(g) any disorder that could interfere with drug absorption, distribution, metabolism, or excretion (including previous gastrointestinal surgery)
- •(h) active, clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other major clinically significant disorder/disease
- •(i) any clinically significant deviation from the normal range(s) in the physical examination or ECG findings, or clinical laboratory test results (ie, serum chemistry, hematology) at the screening or baseline visit
- •(j) absolute neutrophil count (ANC) below the lower limit of normal at screening (NOTE: If the ANC is below the lower limit of normal at the baseline visit, the medical monitor will be consulted for continued eligibility in the study.)
- •(k) seated pulse outside the range of 60 to 115 bpm after resting for 5 minutes
- •(l) a history of alcohol, narcotic, or any other substance abuse or dependence as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IV) criteria
- •(m) a total daily intake of more than 500 mg of caffeine per day (eg, approximately ten 330-mL cans of caffeinated soft drinks, 5 cups of coffee or tea, or about 750 g of chocolate per day) within 1 week of the baseline visit
- •(n) pregnant or lactating/nursing girl; any girl who becomes pregnant during the study will be withdrawn
- •(o) a clinically significant illness within 4 weeks of the baseline visit; or is symptomatic for any clinically significant illness at the baseline visit
研究者
相似试验
进行中（未招募）
1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.MedDRA version: 7.0Level: LLTClassification code 10015595EUCTR2004-002505-74-ESCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.MedDRA version: 7.0Level: LLTClassification code 10015595EUCTR2004-002505-74-GBCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
不适用
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.EUCTR2004-002505-74-CZCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
不适用
A 6-Month Open Label, Flexible Dosage Study to Assess the Safety and Effectiveness of PROVIGIL Modafinil Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeChildren and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeMedDRA version: 6.1Level: HLGTClassification code 10040998EUCTR2004-002505-74-ITCEPHALON EUROPE150
进行中（未招募）
1 期
Efficacy study to evaluate fluticasone furoate /vilanterol Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent AsthmaSubject with persistent asthmaMedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-000551-81-DEGlaxoSmithKline Research & Development Limited422